EnteroBiotix has completed enrolment of patients in a Phase 2 double-blind, placebo-controlled, multi-centre clinical study in irritable bowel syndrome (IBS) and is progressing a Phase 2a study with ...
Hosted on MSN17h
Lower your risk of irritable bowel syndrome by adopting a healthy lifestyle, new study suggestsParticipants who exhibited one behavior had a 21% lower risk of developing IBS symptoms compared with those who followed ... So far, most consensus reports on IBS have focused on diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback